C-reactive protein and the neutrophil-to-lymphocyte ratio are prognostic biomarkers in metastatic renal cell carcinoma patients treated with nivolumab.

Kotaro SuzukiTomoaki TerakawaJunya FurukawaKenichi HaradaNobuyuki HinataYuzo NakanoMasato Fujisawa

Published in: International journal of clinical oncology (2019)

Both the NLR and CRP levels were significantly associated with the clinical outcome of nivolumab in mRCC patients. The potential prognostic impact of those markers needs to be further prospectively investigated.

Keyphrases

end stage renal disease
metastatic renal cell carcinoma
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
risk assessment
patient reported outcomes
atomic force microscopy